The phase 3 NRG GU-005 trial did not show a DFS benefit for SBRT vs IMRT in intermediate-risk prostate cancer, but SBRT decreased rectal toxicity. Stereotactic body radiation therapy (SBRT) preserves ...
SAN FRANCISCO, September 29, 2025 — For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to ...
3don MSN
Israeli hospital's groundbreaking studies could lessen treatments, reduce prostate cancer risks
A groundbreaking study at Rabin Medical Center suggests prostate cancer patients may need only two radiation doses, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results